Senseonics (NYSE:SENS) announced today that it began the launch of its Eversense 365 sensor with the Sequel Med Tech twiist ...
The commercial launch of the integrated products provides people with type 1 diabetes a new level of flexibility and personalization in their diabetes management. Pairing twiist™ with Senseonics’ ...
The FDA has issued a class two device recall for Senseonics’ Eversense continuous glucose monitoring system. This posting follows a September notice from the company that alerted providers and ...
Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetes With a single sensor, the Eversense 365 system provides one year of use, versus ...
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous ...
With a single sensor, the Eversense 365 system provides one year of use, versus 10-14 days with short-term CGM’s for minimal life disruption GERMANTOWN, Md. & PARSIPPANY, N.J.--(BUSINESS ...
GERMANTOWN, Md. and PARSIPPANY, N.J., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (SENS), a medical technology company focused on the development and manufacturing of long-term, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback